Intensified induction therapy with behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine and prednisolone (BHAC-DMP (II)) Therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration

R. Ohno, M. Okumura, S. Yokomaku, Y. Ito, K. Yano, I. T. Sugiura Kataoka, T. Nagai, M. Hamaguchi, T. Kumazawa, T. Murase, T. Kojima, M. Tanimoto, Y. Morishita, E. Nagura, M. Ogura, Y. Morishima, Y. Kodera, K. Kawashima, H. Saito

Research output: Contribution to journalArticle

7 Citations (Scopus)
Original languageEnglish
Pages (from-to)707-716
Number of pages10
JournalActa Haematologica Japonica
Volume53
Issue number4
Publication statusPublished - Jan 1 1990

ASJC Scopus subject areas

  • Hematology

Cite this

Ohno, R., Okumura, M., Yokomaku, S., Ito, Y., Yano, K., Sugiura Kataoka, I. T., Nagai, T., Hamaguchi, M., Kumazawa, T., Murase, T., Kojima, T., Tanimoto, M., Morishita, Y., Nagura, E., Ogura, M., Morishima, Y., Kodera, Y., Kawashima, K., & Saito, H. (1990). Intensified induction therapy with behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine and prednisolone (BHAC-DMP (II)) Therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration. Acta Haematologica Japonica, 53(4), 707-716.